MedTrace Logo

Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)

NCT06561061 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-30

No results posted yet for this study

Summary

A randomized double-blinded placebo-controlled trial of zinc to reduce the incidence of severe or invasive infections in Ugandan children with sickle cell anemia (SCA)

Conditions

Interventions

DRUG

zinc sulfate

Dispersible (20 mg) tablet

DRUG

Placebo

Dispersible tablet

Sponsors & Collaborators

  • Global Health Uganda LTD

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • Indiana University

    lead OTHER

Principal Investigators

  • Chandy C John, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-10
Primary Completion
2025-11-07
Completion
2025-11-07

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561061 on ClinicalTrials.gov